Iseganan (IntraBiotics pharmaceuticals)

Curr Opin Investig Drugs. 2002 Feb;3(2):225-8.

Abstract

Iseganan (IB-367) is a protegrin under development by IntraBiotics, as part of a larger protegrin program, for the potential treatment of oral mucositis, a frequent side effect of anticancer therapies. The company is developing three formulations of the drug: A rinse for the potential treatment of mucositis, an aerosolized liquid for the potential treatment of respiratory infection and a gel formulation for the potential treatment of pneumonia [376325]. Iseganan kills a broad-spectrum of bacteria and fungi, including those resistant to conventional antimicrobial drugs, by attaching to and destroying the integrity of the lipid cell membrane [241594]. Until August 1999, Pharmacia & Upjohn was a codeveloper of iseganan. IntraBiotics re-acquired the global rights to iseganan in December 1999, and both companies agreed to terminate the collaboration [335766]. In May 2000, analysts at SG Cowen predicted the drug's potential market at US $100 to US $200 million [376325].

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Antimicrobial Cationic Peptides
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Drug Industry
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Mouth Mucosa / drug effects
  • Peptides
  • Proteins / pharmacology
  • Proteins / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Stomatitis / drug therapy*
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Drugs, Investigational
  • Peptides
  • Proteins
  • antimicrobial peptide IB-367